Audit: QRS - Somatic Bodywork for Health & Longevity
Audit conducted on 11/09/2026 02:11 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: protocol doses (ER 341–347), time to effect (ER 398), benefit and risk tier headings (ER 155–221, 243–281), contraindications (ER 311–317), interactions (ER 299–307), biomarker table (ER 430–439) and qualitative markers (ER 443–448) all trace to ER text. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | ER “No established target exists; track the change from the individual’s own baseline” (ER 435, 437) is carried as “No established target; track change from own baseline” (QRS 742, 771) without hardening into a numeric target. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications stay contraindications and cautions stay cautions; the ER’s “Caution, not contraindication” anticoagulant bullet (ER 299) sits in Key Interactions, not the stop gate. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Benefits come only from Expected Benefits, risks only from Potential Risks & Side Effects, gates only from Key Interactions & Contraindications; no Benefit- or Risk-Modifying Factor content appears on the sheet. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, author names or brand names appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | The only study-adjacent references — “the neck-pain subgroup analysis” (QRS 485) and “the pooled Feldenkrais data” (QRS 707) — are ER phrasings (ER 347, 432). |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s measured, conflict-aware register, including carrying the ER’s “has not reliably added benefit” caveat into the lede. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Leads with the strongest signal and actionable dosing before costs, while keeping the ER’s objectivity. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Descriptive throughout (“Single sessions performed no better than placebo”), no imperatives. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Gates and monitoring targets are stated as facts drawn from the ER; the template disclaimer is intact (QRS 866–869). |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommended”, “should”, or “advised” in the document’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms carry the ER’s own plain glosses (“rest-and-digest”, “blood-thinning treatment”). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every gate, benefit and risk item is a single short clause; monitoring rows are trimmed to marker/target/why. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by search for you/your/yours/yourself — no matches. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Full-course dosing, baseline/retest cadence and self-tracked markers assume a proactive optimizer. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | A 24-lesson one-to-one course and an 8-sessions-in-4-weeks schedule are presented without hedging on cost or effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplified “try a massage” framing; the under-dosing pitfall is reflected in the protocol cell instead. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The lede names the add-on-to-rehabilitation null result, which is the decision-relevant distinction for an audience already doing structured rehabilitation. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not appear; the title and marker_7_why use “Longevity” / “longevity endpoint”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Formal terms are used for named entities (“anticoagulant and antiplatelet drugs”, “myocardial infarction”, “international normalised ratio”); the remaining lay-register phrases (“blood-thinning treatment”, “rest-and-digest”) are the ER’s own explanatory wording (ER 311, 135). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | A content-stripped diff against [qrs_template] shows zero differences outside the variable spans and the metadata block; all headings, tier labels and column headers are byte-identical. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Every template span name is present; marker_#_* and qualitative_item_# are correctly expanded to marker_1–10 and qualitative_item_1–6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The non-variable spans website="evidence_review", website="audit" and website="full_review" are untouched, as are the stylesheet, CSS and footer. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section feeding the QRS is empty — all four benefit tiers, all four risk tiers, contraindications, interactions, protocol and monitoring are populated in the ER. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels “Alexander Technique lesson course”, “Feldenkrais two-track course” and “Massage and myofascial release dosing” (QRS 450, 464, 478) are the ER’s bold labels verbatim (ER 341, 343, 347). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Monitoring marker names and qualitative-item leads also match the ER table and list exactly. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Unicode emoji search returns no matches; the ER’s ⚠️ “Conflicted” flags were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to its minimum form — tier lines are single semicolon-separated clauses, gate items are single lines, and monitoring “why” cells are one short phrase each. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | QRS 2–14: the metadata comment immediately follows <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at QRS 3, closing --- at QRS 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Wholly inside an HTML comment; no metadata value is repeated in the header, footer or body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:02" is quoted, which is required because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | QRS 4: er_filename: somatic_bodywork_2026-0911-0008_Opus_ER.md, matching the ER’s own filename frontmatter (ER 17). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | QRS 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | QRS 6: qrs_creation_date: 2026-0911-0205. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | QRS 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | QRS 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | QRS 9: qrs_filename: somatic_bodywork_2026-0911-0008_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys including the appended git_user and git_issue; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | QRS 22: “Somatic Bodywork for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic (ER 8) with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | QRS 417: “Somatic Bodywork for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | QRS 421: “09/11/2026”, correct reformatting of 2026-0911-0205. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | QRS 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header block (QRS 415–428) contains only the template’s title, date, evidence-review span, AI4L link, model name and audit span. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER 468–470: nature of the practice, strongest signal, secondary effects, costs, and the add-on null result. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 56 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each of the five clauses maps to a distinct sentence in ER 468–470. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “lesson-based methods”, “passive treatment” and “standard rehabilitation” are lay-comprehensible. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years or sample sizes. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numbers of any kind appear in the lede. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All seven items come from the ER’s “Populations who should avoid Somatic Bodywork” list (ER 311–317). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All seven ER avoid-populations are represented, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Seven <li> elements inside the stop_items span (QRS 574–597). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s em-dash clauses were converted to compact parentheticals or dropped; the T-score gloss (“the T-score compares bone density against a young-adult average”, ER 313) and the “(heart attack)” gloss (ER 316) were removed. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | The two-week anticoagulation window, the 50 × 10⁹/L and INR 4.0 thresholds, the −2.5 T-score, NYHA Class IV, the 90-day infarct window and the “at the treated site” scope are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s contraindication list uses no ranking notation inside parentheses; thresholds are stated in words (“below”, “above”). |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER identifies seven such populations, and the section is correspondingly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All five items come from the ER’s interaction bullets (ER 299–307). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All five ER interactions are present and none duplicates a stop-gate item; the ER explicitly marks the anticoagulant bullet “Caution, not contraindication” (ER 299). |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Five <li> elements inside the caution_items span (QRS 603–624). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER Caution/Monitor label plus its Consequence and Mitigation sentences were stripped, as were the em-dash glosses “medicines that slow clotting” and “pain-relieving drugs”. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All five ER example-drug lists are carried verbatim (warfarin/apixaban/rivaroxaban/clopidogrel/aspirin; ibuprofen/naproxen/paracetamol; menthol/capsaicin/lidocaine patches; fish oil/vitamin E/ginkgo/garlic/nattokinase/curcumin; antihypertensives/magnesium/beetroot nitrate/hibiscus). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction parentheticals are plain comma-separated drug lists with no ranking notation. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER identifies five such interactions, and the section is correspondingly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from the ER Therapeutic Protocol bullets (ER 341, 343, 347). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Alexander lessons, the Feldenkrais course and massage/myofascial dosing are the three protocols tied to the ER’s high-tier benefits (spinal pain, balance, pain), ahead of the Structural Integration and Somatic Experiencing courses. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER lists five distinct dosing protocols, so no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans are populated: e.g. “24 lessons, 30–40 min” from ER 343 and “≥8 sessions / 4 weeks, ≥30 min” from ER 347. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | All three sets are populated and map to the three aspects in ER 398: pain and disability at six lessons (QRS 498–507), balance at five weeks (QRS 512–520), and single-session relaxation and pain relief (QRS 525–531). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Pain and disability (largest high-tier effect, ER 159) is placed before the balance and relaxation cells. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER states three distinct time-to-effect aspects (ER 398), so no set should be unused. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | The populated sets carry ER-derived content: “6 lessons” and “5 weeks” and “Single session” all trace to ER 398. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information (ER 398), so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All eleven items are the ER’s own benefit subheadings (ER 155–221). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans are present and populated (QRS 541–565). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-separated list of bare benefit statements; no Magnitude figures (3.4 RMDQ points, 1.14 s, 7.39 mmHg) were carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits span. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain items, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All six items are the ER’s own risk subheadings (ER 243–281). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans are present and populated (QRS 635–652). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Frequencies (1.5%–25%), the twenty published reports and the “Not quantified in available studies” notes were all dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks span; the ER’s glosses for haematoma and pulmonary embolism were removed. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain items, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Marker names, targets and rationales come from the ER Monitoring Protocol & Defining Success table (ER 428–439). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All ten ER table rows are present as marker_1 through marker_10, in the ER’s order. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | QRS 811–816 condenses ER 426 and the DXA note in ER 439: baseline, after six sessions, end of course, then six-to-twelve-monthly, with post-session blood pressure and two-yearly bone density. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items come from the ER’s qualitative-marker list (ER 443–448). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | Ease and effort, morning stiffness, sleep quality, postural self-catching, emotional regulation and fear of movement — all six, in ER order. |
Issues 11/09/2026 02:11
Pass rate 100.00%. No issues found.